The importance of schedule in whole body thermochemotherapy
/in Breast Cancer, Hyperthermia, International PublicationsDendritic cell based genetic immunization stimulates potent tumor protection dependent on CD8 CTL cells in the absence of autoimmunity
/in International Publications, Malignant MelanomaOncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses
/in International Publications, Newcastle Disease VirusSecond International Conference on Cancer Vaccines/Adjuvants/Delivery for the Next Decade (CVADD): Heidelberg, Germany, 10-12 October 2007
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease VirusDendritic cell vaccines in melanoma: from promise to proof?
/in Dendritic Cells, International Publications, Malignant MelanomaImmunisation with ’naïve‘ syngeneic dendritic cells protects mice from tumour challenge
/in Breast Cancer, International PublicationsDendritic cell vaccination induces tumor epitope-specific Th1 immune response in medullary thyroid carcinoma
/in Dendritic Cells, International Publications, Thyroid CancerImmunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond
/in International Publications, Malignant Lymphoma[Dendritic cells elicit cellular immune response by targeting to capture breast cancer cells]
/in Breast Cancer, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer